# ROADMAP_STATUS.md — ANTIBIO

**Progress overview. Evidence-based where possible.**

**Date:** 2026-07-10

## Architecture
- v3 — **FROZEN** (100%)
- All foundational principles and layers locked.

## Engineering
- Master Plan + Backlog — **ACCEPTED** (100%)
- P0-1 BundleManifest — **CLOSED + FROZEN**

## Execution (Phase 0 — COMPLETE + FROZEN)
- P0-1..P0-4: **COMPLETE + FROZEN**.
- See P0_COMPLETION_REPORT.md.
- P1-A Drug Terminology: COMPLETE + FROZEN. P1-B Diagnosis Terminology: analysis done (exact match only, no synonyms/trace, conflicts).
- Process complete. No new rules. Impl + Optimization Rule (permanent). Traceability law.

## Testing & Assurance
- Core engine tests + invariants: Green (clinical 298+ passed 0 failed post P2-1)
- Golden cases infrastructure: Ready (M12)
- P2-1 Conformance: COMPLETE + FROZEN
- Full coverage metrics (A/B/C runtime): Analysis only (P2-2)

## Validation / Content
- Data Quality Audit + RCA: Done (read-only)
- Dataset Pruning simulation: Done
- Curation (diagnosis_index, LEVEL A): Pending (physician task)
- Golden Clinical Cases (real cases): Pending (physician + AI review)

## MVP Readiness
- Core kernel + ports + bundles + terminology + eval + governance partial + packaging: **~40-50%** (qualitative; gated by P0-2 + P1 + P2 + DQ-C + P7)

## Production
- Not started. Requires full curation, golden cases, safety verification, P7.

## Evidence
- Test count: 1159 passed (measured)
- Regimens: 2675 (from normalized data)
- Guidelines with antibiotic data: 291 (measured from issues)
- Unique in index: 294 (measured)

**Next blocker:** Complete P0-2, then unblock P1/P2.
